《大行》大摩降东阳光长江药业(01558.HK)目标价至12.6元 下调盈测

阿斯达克财经
24 Dec 2024


摩根士丹利发表研报指,鉴于今年第四季流感发病率数据疲弱,该行将东阳光长江药业(01558.HK) 2024至2030财年盈利预测下调9%至11%,主要由于抗病毒药物销售额下降。
大摩亦预计,抗病毒药物“奥司他韦”2024年及往后的销售额,将恢复至疫情前50亿元人民币或更高水平。该行将东阳光长江药业目标价由13.8港元下调至12.6港元,给予“增持”评级。(js/W)

(港股报价延迟最少十五分钟。沽空资料截至 2024-12-23 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10